Cholesterol can reduce the lipid bilayer fluidity in lamellar liquid crystalline systems. As such, it is an essential component of cell membranes and in liposome formulations for drug delivery.Non-lamellar structured liquid crystalline systems also have a relevant role in biology, and have potential advantages over liposomes as drug delivery agents. This project investigates the effects of cholesterol on the internal structure and bilayer fluidity of non-lamellar liquid crystalline nanoparticles, hexosomes and cubosomes, and consequent impact on their drug encapsulation and release properties. The insight gained in this project helps to further engineer cubosomes and hexosomes as drug delivery agents.
|Effective start/end date||1/07/13 → 30/06/14|
- Australian Institute of Nuclear Science and Engineering (AINSE): AUD7,830.00